Core Insights - New car prices are at an all-time high, with average monthly payments reaching $766 and average amounts financed at $43,218, driving consumers towards the used car market [1][2] - Companies like Carvana, Autoation, and CarMax are benefiting from this trend, with stock prices increasing significantly [2] - Valvalene, which operates 2,300 car servicing stores, is positioned to capitalize on the growing demand for maintenance services as consumers hold onto their older vehicles longer [2][3] Company Performance - Valvalene's CEO noted that the average age of vehicles in the U.S. has increased to nearly 13 years, leading to higher maintenance needs and revenue opportunities for the company [4] - The company has been experiencing a steady influx of customers seeking maintenance for their older vehicles, which aligns with the trend of consumers opting for used cars over new ones [3][4] - Valvalene's growth in the electric vehicle (EV) segment has slowed since the removal of EV subsidies, with EV penetration in the car park currently below 2% [6][7] Market Dynamics - The shift towards maintaining older vehicles rather than purchasing new ones is expected to continue, as consumers find it more economical to keep their current cars [5] - Valvalene's hybrid business is performing well, with penetration rates comparable to traditional internal combustion engine vehicles [8] - The company aims to improve its market perception and investor understanding following a significant acquisition and a focus on clear financial commitments for growth [12][10] Community Engagement - Valvalene has a strong commitment to community involvement, having raised over $1.8 million for the Children's Miracle Network and engaging in various charitable activities [15][16]

Core Viewpoint - The article discusses the current landscape of heavily shorted stocks, highlighting the reasons traders engage in short selling and the potential for short squeezes as investment opportunities [2][3][4]. Summary by Sections Heavily Shorted Stocks - Stocks become heavily shorted when experienced traders and institutional investors believe the company is fundamentally overvalued, anticipating a price decline [2]. - Short sellers borrow shares, sell them at high prices, and aim to repurchase them at lower prices for profit, indicating a strong conviction about the company's risks [3]. Current Market Data - As of December 10, 2025, the top 10 most shorted stocks with market caps above $2 billion and free floats above 5 million are listed, ranked by short interest percentage [5]. - The most heavily shorted stock is Lucid Group, Inc. (NASDAQ: LCID) with a short interest of 52.70%, followed by Avis Budget Group, Inc. (NASDAQ: CAR) at 51.53% and Choice Hotels International, Inc. (NYSE: CHH) at 49.05% [6][7]. Market Characteristics - Heavily shorted stocks often reflect a battleground between negative fundamentals and speculative trading, where short squeezes can lead to significant, rapid gains but also come with high risk and volatility [8]. - Monitoring short interest can help identify potential short squeeze candidates, although timing such trades is challenging [8].

A major fund walking away from a recovering operator is always a good opportunity to reassess the company's fundamentals.Toronto-based Maple Rock Capital Partners sold out its entire position in Avis Budget Group (CAR +1.30%), reducing its holdings by 415,584 shares in the third quarter in a move valued at $70.3 million, as disclosed on November 14.What HappenedMaple Rock Capital Partners disclosed in a November 14 SEC filing that it fully exited its stake in Avis Budget Group (CAR +1.30%) during the quarte ...

Core Viewpoint - Carmakers BMW and Toyota, along with auto rental and leasing firms from Europe, are advocating against the European Commission's proposal to set mandatory targets for electric vehicle purchases for corporate fleets [1] Group 1 - BMW and Toyota are leading the charge in opposing mandatory electric vehicle purchase targets [1] - The automotive industry is concerned about the implications of such regulations on corporate fleets [1] - The request was made to the European Commission, highlighting the industry's collective stance [1]

Core Points - BMS's Breyanzi has been approved by the U.S. FDA as the first and only CAR T cell therapy specifically for adults with relapsed or refractory marginal zone lymphoma (MZL) [1] Company Summary - The approval of Breyanzi represents a significant advancement in the treatment options available for patients suffering from MZL, a type of non-Hodgkin lymphoma [1] - This approval may enhance BMS's position in the oncology market, particularly in the CAR T cell therapy segment [1] Industry Summary - The approval of Breyanzi could lead to increased competition in the CAR T cell therapy market, as it sets a precedent for future therapies targeting specific lymphoma types [1] - The development of targeted therapies like Breyanzi reflects a growing trend in the pharmaceutical industry towards personalized medicine [1]

Core Insights - Avis Budget Group reported strong Q3 2025 earnings, with adjusted earnings per share of $10.11, exceeding estimates by 24.7% and increasing 52% year-over-year [2] - Revenues reached $3.5 billion, surpassing the consensus estimate by 1.1% and showing a 1.1% year-over-year growth [2] Segment Performance - Revenues from the Americas were $2.6 billion, reflecting a 1% decline from the previous year, but met estimates [3] - International revenues increased to $898 million, up 7% year-over-year, exceeding the estimate of $863.6 million [3] Profitability Metrics - Adjusted EBITDA for the company was $559 million, an 11% increase from the year-ago quarter [4] - The Americas segment reported adjusted EBITDA of $398 million, a 4% year-over-year increase, while international adjusted EBITDA was $190 million, up 37% [4] Financial Position - At the end of Q3 2025, Avis Budget had cash and cash equivalents of $564 million, up from $541 million at the end of Q2 2025 [5] - Corporate debt remained stable at $6.1 billion, and the company generated $1.4 billion in net cash from operating activities [5] Estimate Trends - Consensus estimates for the stock have trended downward, with a significant shift of -112.21% noted [6] - Avis Budget currently holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [9] VGM Scores - The company has a strong Growth Score of A, but a lower Momentum Score of D, while maintaining an overall aggregate VGM Score of A [7]

Group 1 - The article provides a market analysis focusing on key companies including FedEx Corporation, CH Robinson Worldwide Inc, and Union Pacific Corporation, as well as the Dow Jones Industrial Average [1] Group 2 - FedEx Corporation's performance is analyzed in the context of its operational efficiency and market positioning [1] - CH Robinson Worldwide Inc is discussed regarding its logistics services and market trends affecting its growth [1] - Union Pacific Corporation's operational metrics and impact on the transportation sector are highlighted [1]

Core Insights - Bristol Myers Squibb has received approval from the European Commission to expand the use of its CAR T cell therapy, Breyanzi, for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor [1][2][4] Group 1: Clinical Efficacy - In the TRANSCEND MCL trial, Breyanzi demonstrated an overall response rate of 82.7% and a complete response rate of 71.6% among patients treated in the third-line plus setting [2][3] - The therapy showed sustained clinical benefit, with 50.8% of patients still in response at 24 months [1][2] - The median time to first response was 0.95 months, indicating rapid efficacy [2] Group 2: Safety Profile - The safety results for Breyanzi were consistent with its established profile, with cytokine release syndrome (CRS) occurring in 61% of patients, and only 1% experiencing grade three or four CRS [3][19] - Neurologic toxicities were reported in 31% of patients, with grade three or four cases in 9% [3][19] - The majority of adverse events occurred within the first 14 days post-infusion, allowing for early resolution and adjustments to monitoring requirements [3] Group 3: Regulatory and Market Implications - This approval is applicable across all EU member states and EEA countries, marking the fourth approval for Breyanzi in Europe [4][5] - Breyanzi is also approved for other indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma [4][9] - Bristol Myers Squibb is positioned as a leader in cell therapy, with a focus on expanding treatment options for aggressive forms of non-Hodgkin lymphoma [34][36]

Core Insights - Broad Arrow Auctions, a Hagerty company, is launching a new online auction series called Global Icons in January 2026, featuring collector cars and motorsport memorabilia [1][2] Auction Format and Offerings - Global Icons will consist of three parts: two online collector car auctions (Global Icons: Europe Online and Global Icons: UK Online) and an online memorabilia auction (Global Icons: Memorabilia Online) [1][2] - The auctions will feature a diverse selection of high-quality pre-war, post-war, and modern collector cars, with a focus on 'iconic' vehicles that hold historical significance [2][3] Featured Lots - A notable early consignment for the auctions includes a 1971 Lamborghini Miura P400 S, estimated between €1.600 million and €1.800 million, which has a rich history and has been carefully restored [3][4] Memorabilia Offerings - The memorabilia auction will include approximately 100 lots, featuring items associated with legendary drivers such as Ayrton Senna and Michael Schumacher [5] Auction Timeline - Bidding for the auctions will open on January 23, 2026, with the Europe and UK Online auctions closing on January 30, and the Memorabilia Online auction closing on February 1 [6] In-Person Previews - Broad Arrow will host in-person previews of many auction lots at various locations across Europe and at its UK headquarters, enhancing the auction experience for bidders [7] Consignment Information - Interested consignors are invited to connect with Broad Arrow for consignment opportunities, with buyer's premiums set at 10% for collector vehicles and 25% for memorabilia [8]

Core Insights - Anixa Biosciences has received approval from the WHO for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant milestone in its development and potential commercialization [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) expressed on ovarian cells and certain cancer cells [3][4] Clinical Development - The ongoing Phase 1 trial of liraltagene autoleucel is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3][4] - The trial is being conducted in partnership with Moffitt Cancer Center, a leader in cancer immunotherapy [2][4] Future Directions - The approval of the non-proprietary name allows Anixa to establish a universally recognized name for its CAR-T therapy, facilitating clearer identification and safe prescription of the drug [2][3] - The company plans to transition to using the name liraltagene autoleucel, or lira-cel, in future communications [2]